DBL HYOSCINE HYDROBROMIDE

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Hyoscine hydrobromide

Available from:

Hospira Australia Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

DBL
™
 Hyoscine Injection BP CMI 
Page 1 
DBL™ HYOSCINE INJECTION BP 

Hyoscine hydrobromide _(HYE-oh-seen HYE-droe BROE-mide) _

CONSUMER MEDICINE INFORMATION  
_Date of Dispensing _
_Consumer Name _
_Pharmacist Name _
_Consumer Address _
_Pharmacist Address _
_ _

WHAT IS IN THIS LEAFLET 

This leaflet answers some 
common questions about DBL™ 
Hyoscine Injection BP (hyoscine).  
It does not contain all the 
available information. 

It does not take the place of 
talking to your doctor and 
pharmacist. 

All medicines have risks and 
benefits.  Your doctor has 
weighed the risks of you being 
given DBL™ Hyoscine Injection 
BP against the benefits this 
medicine is expected to have for 
you.   

IF YOU HAVE ANY CONCERNS ABOUT 
THIS MEDICINE, ASK YOUR DOCTOR OR 
PHARMACIST. 

KEEP THIS LEAFLET IN A SAFE PLACE.  
You may need to read it again. 

WHAT DBL™ HYOSCINE 
INJECTION BP IS USED 
FOR 

DBL™ Hyoscine Injection BP is 
used before surgery to make you 
drowsy and forgetful, and to 
reduce the amount of saliva and 
some fluids you produce in your 
lungs. It is also used to treat 
nausea and vomiting from motion 
sickness. 

Hyoscine works by acting directly 
on your brain, salivary glands and 
air passages to reduce nerve 
impulses and slow down the 
activity of these areas. 
Your doctor may have prescribed 
DBL™ Hyoscine Injection BP for 
another reason.  Ask your doctor 
if you have any questions about 
why this medicine has been 
prescribed for you. 

BEFORE YOU ARE GIVEN 
DBL™ HYOSCINE 
INJECTION BP 

_WHEN YOU MUST NOT BE _
_GIVEN IT _

DBL™ HYOSCINE INJECTION BP 
SHOULD NOT BE GIVEN TO YOU IF: 

•  YOU HAVE AN ALLERGY TO 
HYOSCINE. 
Some of the symptoms of an 
allergic reaction to hyoscine 
may include skin rash, itching, 
difficulty breathing and 
swelling, especially of the face 
and throat. 
•  THE PACKAGING IS TORN OR 
SHOWS SIGNS OF TAMPERING 
•  THE EXPIRY DAT

Summary of Product characteristics

Product Information – Australia 

Version 5.0 

Page 1

DBL™ HYOSCINE INJECTION BP 

NAME OF MEDICINE 
Hyoscine Hydrobromide BP 

O
O
H
OH
H
N
CH
3
O
HBr
3H
2
O

The molecular formula of hyoscine hydrobromide is C
17
H
21
NO
4
.HBr.3H
2
O.  Its molecular weight is 
438.3.  The CAS Registry number of hyoscine hydrobromide.3H
2
O is 6533-68-2. 

DESCRIPTION 

DBL™ Hyoscine Injection BP is a clear, colourless to straw
coloured, sterile solution of hyoscine 
hydrobromide.3H
2
O in Water for Injections.  Each mL contains 0.4 mg of hyoscine
hydrobromide 
trihydrate in Water for Injections.  The pH of the solution is
between 3.8 and 4.2. 

PHARMACOLOGY 
Hyoscine is a belladonna alkaloid.  Hyoscine hydrobromide is a
tertiary amine antimuscarinic agent, 
which competitively antagonizes acetylcholine.  The main
pharmacologic actions of hyoscine 
hydrobromide are a decrease in the production of salivary, bronchial
and sweat gland secretions, 
dilated pupils (mydriasis), paralysis of accommodation (cycloplegia),
a decrease in micturition, a 
decrease in gastrointestinal tone and gastric secretion, and
bradycardia although transient tachycardia 
may be observed at higher doses. 

The effects of hyoscine hydrobromide differ from those of atropine in
that hyoscine hydrobromide has 
a more potent effect on the iris,
ciliary body and some secretory glands than atropine, and a
less 
potent effect on the heart, intestine and bronchial muscle.  Its
effect on the gastrointestinal tract have 
lead to its use as an antispasmodic in irritable bowel syndrome.
 Unlike atropine, hyoscine 
hydrobromide usually produces CNS depression at therapeutic doses,
although CNS stimulation 
occurs at higher doses, and may also occur when hyoscine
hydrobromide is used in the presence of 
pain.  Hyoscine hydrobromide does not usually produce the increased
respiration rate or blood 
pressure observed with atropine administration. 

PHARMACOKINETICS